Enteris BioPharma Inc

Enteris BioPharma Inc. is a clinical stage biopharmaceutical company headquartered in Boonton, New Jersey. The company employs 12 people and generates annual revenue exceeding $10,000. Enteris BioPharma operates as a wholly-owned subsidiary of SWK Holdings Corporation. Enteris BioPharma specializes in developing innovative oral drug delivery solutions based on its proprietary Peptelligence® platform. This technology enables the oral administration of peptide-based therapeutics and other molecules with low oral bioavailability. The company offers formulation development expertise and operates a 32,000 square foot GMP facility in Boonton, New Jersey, providing manufacturing and development services. Enteris BioPharma's internal product pipeline includes Ovarest® (oral leuprolide tablet) for endometriosis and Tobrate™ (oral tobramycin tablet) for uncomplicated urinary tract infections (uUTIs). The company's Peptelligence® platform is also utilized in externally sponsored pre-clinical and clinical development programs, including R-Pharm’s TBRIA, an oral calcitonin for osteoporosis, and Cara Therapeutics’ KORSUVA™, an oral formulation for pruritus treatment. For more information, visit enterisbiopharma.com.